Regeneron Reports Second Quarter 2020 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Regeneron Reports Second Quarter 2020 Financial and Operating Results
August 6, 2020 8:13 AM EDT
Cowen analyst Yaron Werber raised the price target on Regeneron Pharma (NASDAQ: REGN) to $684.00 (from $584.00) while maintaining a Market Perform rating.
The analyst commented, "Solid Q2 was driven by strong global Dupi and Eylea sales with modest impact of COVID-19. The neutralizing antibody... More
August 5, 2020 6:39 AM EDT
Regeneron (NASDAQ: REGN) reported Q2 EPS of $7.16, $1.18 better than the analyst estimate of $5.98. Revenue for the quarter came in at $1.95 billion versus the consensus estimate of $1.74 billion.
Second quarter 2020 revenues increased 24% to $1.95 billion versus second quarter 2019(4)
Second quarter 2020 EYLEA® U.S. net sales were $1.11 billion
Second quarter 2020 Dupixent® global net sales(2), which are recorded by Sanofi, were $945 million
Second quarter 2020 GAAP diluted EPS was $7.61 and non-GAAP diluted EPS(1)...
More
